Latest Breaking News On - Arun chandavarkar - Page 1 : comparemela.com

Biocon Share Price Graph And News - StockManiacs

Shreehas Tambe appointed as Managing Director & CEO of Biocon Biologics Ltd

Biocon Biologics appoints Shreehas Tambe as MD, CEO

Biocon Biologics (BBL), a subsidiary of Biocon, has announced that Shreehas Tambe has been appointed as its managing director and CEO with effect from Monday.

Shreehas Tambe appointed as MD & CEO of Biocon Biologics

Tambe has taken over from Arun Chandavarkar, who continues to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics

Biocon Q2FY23 Revenue at Rs 2,384 Cr., Up 23 percent; Core EBITDA at Rs 816 Cr., Up 34 percent Gross R&D Spend at Rs 252 Crore, Up 52 percent

Bengaluru (Karnataka) [India], November 15 (ANI/NewsVoir): Biocon Ltd. (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the second quarter ended September 30, 2022. Leadership Comments Biocon Group "We reported a strong consolidated revenue growth of 23 per cent YoY for Q2FY23 at Rs. 2,384 Crore driven by 34 per cent growth in Biosimilars, 26 per cent in Research Services and 18 per cent in the Generics business. Our Gross R&D spends increased by 52 per cent YoY this quarter to Rs. 252 Crore reflecting our advancing pipeline that will drive our future growth. Core EBITDA was up by 34 per cent at Rs. 816 Crore, representing healthy core operating margins of 35 per cent versus 33 per cent in the same quarter last year. "We have delivered a resilient performance in H1FY23, with all segments delivering strong revenue growth. We expect to consolidate on this performance in the second ha